Not actual size.
The first and only FDA-approved RTU vasopressin with up to 12 months of room temperature stability
Vasostrict® is a sterile, aqueous solution of synthetic arginine vasopressin for intravenous administration.1 Vasopressin is a polypeptide hormone. Vasostrict® is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines.
Vasostrict® premixed solution comes in ready-to-use, single-dose vials that do not require further dilution prior to administration.1
 | May offer enhanced inventory management with up to |
| | Preservative-free |
| | Available through your wholesaler |
| | Does not require compounding, diluting, mixing, or transferring, which may reduce waste and chance of preparation error3 |
| | Compatible with most automated dispensing machines |
| | Aligns with medication strategies of ASHP Guidelines on Preventing Medication Errors in Hospitals3 |
| † | Room temperature (20°C to 25°C or 68°F to 77°F) upon removal from refrigeration. Recommended storage is under refrigerated conditions from 2°C to 8°C (36°F to 46°F); do not freeze.1,2 |
INDICATION
Vasostrict® is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines.
IMPORTANT SAFETY INFORMATION FOR VASOSTRICT®
CONTRAINDICATIONS
Vasostrict® 10 mL multiple dose vial is contraindicated in patients with known allergy or hypersensitivity to 8-L-arginine vasopressin or chlorobutanol. The 1 mL single dose vial and 100 mL pre-mixed single dose vial does not contain chlorobutanol and is therefore contraindicated only in patients with a known allergy or hypersensitivity to 8-L-arginine vasopressin.
WARNINGS AND PRECAUTIONS
Worsening Cardiac Function
A decrease in cardiac index may be observed with the use of vasopressin.
REVERSIBLE DIABETES INSIPIDUS
Patients may experience reversible diabetes insipidus, manifested by the development of polyuria, a dilute urine, and hypernatremia, after cessation of treatment with vasopressin. Monitor serum electrolytes, fluid status and urine output after vasopressin discontinuation. Some patients may require readministration of vasopressin or administration of desmopressin to correct fluid and electrolyte shifts.
ADVERSE REACTIONS
The most common adverse reactions include decreased cardiac output, bradycardia, tachyarrhythmias, hyponatremia and ischemia (coronary, mesenteric, skin, digital).
DRUG INTERACTIONS
Catecholamines
Use with catecholamines is expected to result in an additive effect on mean arterial blood pressure and other hemodynamic parameters. Hemodynamic monitoring is recommended; adjust the dose of vasopressin as needed.
Indomethacin
Use with indomethacin may prolong the effect of Vasostrict® on cardiac index and systemic vascular resistance. Hemodynamic monitoring is recommended; adjust the dose of vasopressin as needed.
Ganglionic Blocking Agents
Use with ganglionic blocking agents may increase the effect of Vasostrict® on mean arterial blood pressure. Hemodynamic monitoring is recommended; adjust the dose of vasopressin as needed.
Drugs Suspected of Causing SIADH
Use with drugs suspected of causing SIADH (e.g., SSRIs, tricyclic antidepressants, haloperidol, chlorpropamide, enalapril, methyldopa, pentamidine, vincristine, cyclophosphamide, ifosfamide, felbamate) may increase the pressor effect in addition to the antidiuretic effect of Vasostrict®. Hemodynamic monitoring is recommended; adjust the dose of vasopressin as needed.
Drugs Suspected of Causing Diabetes Insipidus
Use with drugs suspected of causing diabetes insipidus (e.g., demeclocycline, lithium, foscarnet, clozapine) may decrease the pressor effect in addition to the antidiuretic effect of Vasostrict®. Hemodynamic monitoring is recommended; adjust the dose of vasopressin as needed.
OVERDOSAGE
Overdosage with Vasostrict® can be expected to manifest as consequences of vasoconstriction of various vascular beds (peripheral, mesenteric, and coronary) and as hyponatremia. In addition, overdosage may lead less commonly to ventricular tachyarrhythmias (including Torsade de Pointes), rhabdomyolysis, and non-specific gastrointestinal symptoms.
Direct effects will resolve within minutes of withdrawal of treatment.
Please see the Full Prescribing Information for Vasostrict®.
Please see the Technical Bulletin on Dextrose 5% Information for Vasostrict®.
References: 1. Vasostrict®. Prescribing Information. Endo USA, Inc. 2. Data on file. DOF-VS-02. Endo USA, Inc.; September 20, 2023. 3. American Society of Health-System Pharmacists. ASHP guidelines on preventing medication errors in hospitals. Am J Health-Syst Pharm. 2018;75(19):1493-1517.